Advaxis (ADXS) Trading Higher Following Positive KEYTRUDA Data from Merck

Shares of Advaxis, Inc. (ADXS) are higher by 5.72% to $14.01 in late morning trading on Tuesday following positive KEYTRUDA data from Merck (MRK). Merck this morning announced that the pivotal Phase 3 study (KEYNOTE-006) investigating KEYTRUDA (pembrolizumab) compared to ipilimumab in the first-line treatment of patients with advanced melanoma has met its two primary […] View the full post at: Advaxis (ADXS) Trading Higher Following Positive KEYTRUDA Data from Merck Related posts: Economic Data: CPI Higher than Expected China Facing Electricity Shortages On Higher Coal Prices Economic Data for the Week of Sept. 8 – 11